Q-omics provides the consensus-scored MIR6746 profile across patient tissues and cancer cell-line models. MIR6746 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR6746 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, MIR6746 RNA expression shows 11,725 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, BRCA, and UVM as cancer lineages where MIR6746 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6746 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6746 survival associations across molecular data types. MIR6746 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6746 RNA expression–survival associations across cancer types. High MIR6746 expression shows unfavorable associations in ACC, LUSC, THCA, ESCA and LGG, but favorable associations in SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR6746 RNA expression.
This table summarizes MIR6746 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6746. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6746 shows lower tumor expression in BRCA and LUAD and higher tumor expression in CHOL, COAD, KIRC and HNSC. The BRCA box plot shows higher MIR6746 RNA expression in normal versus tumor tissue (log2 FC = −0.951, t-test p < 0.001).
This table shows molecular features associated with MIR6746 in patient tissues and cancer cell lines. In patient samples, MIR6746 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
